Overview

Tumor 56 Gene Testing uses next-generation sequencing to interrogate 20 targeted-therapy genes and 36 chemotherapy-related genes from a single tumor sample. The panel is deliberately compact: rather than scanning the whole exome, it focuses on a curated set of genes with established relevance to treatment decisions. Understanding the sequencing mechanism helps buyers appreciate why a smaller, well-designed panel can deliver fast, interpretable results without the complexity of ultra-large profiling.

From Tissue to Sequence

The workflow begins with DNA extracted from formalin-fixed, paraffin-embedded tissue. Selected gene regions are enriched, commonly by hybrid-capture or amplicon preparation, and then sequenced on a high-throughput instrument. Bioinformatics pipelines align the reads, call variants, and annotate them against clinical databases. Because only a defined gene set is enriched, the sequencing depth per gene is high, which supports reliable detection of variants present at modest frequency within a heterogeneous tumor.

Why a Focused Gene Set Helps

A compact panel trades breadth for clarity. By limiting coverage to genes with actionable or pharmacogenomic meaning, the report stays concise and the variant classification burden is lower, reducing the chance of incidental findings that complicate care. For resource-conscious programs, this focus also shortens turnaround and lowers cost relative to thousand-gene assays, while still covering the drivers most likely to change therapy in common tumor types.

Interpreting the Two Tracks

The 20 targeted genes point to alterations that may match approved agents or trials, while the 36 chemotherapy genes supply pharmacogenomic context that can inform cytotoxic choices. Presenting both in one report lets the clinician weigh a targeted route against a chemotherapy plan using a single molecular dataset. The mechanism is the same throughout; only the clinical interpretation differs between the two gene groups.

Turning Results Into a Plan

The compact design does not reduce clinical utility when the covered genes are well chosen. Once the targeted and chemotherapy tracks return, the team can match an alteration to an approved option or use the pharmacogenomic data to adjust cytotoxic dosing. Because the report is short, the decision points stand out clearly, which suits programs that need fast turnaround without sacrificing the key markers that guide therapy.

Quality Gates That Protect the Call

Reliable results depend on quality gates built into the pipeline. Before variants are reported, the assay should meet coverage and uniformity thresholds for every targeted region, and flagged calls should pass contamination and strand-balance checks. Presenting these metrics in the report lets buyers verify that a negative result reflects a true absence rather than shallow sequencing, which is essential when a compact panel is used to rule out a driver.

FAQ

Q: How does a 56-gene panel achieve reliable calls with fewer genes? A: Enriching only selected regions concentrates sequencing depth on those genes, improving detection of lower-frequency variants.

Q: Is a compact panel less accurate than a large one? A: Accuracy depends on assay validation; a focused panel can be highly accurate for its covered genes and is faster to interpret.

Q: What sample type is required? A: The test is designed for DNA from formalin-fixed, paraffin-embedded tumor tissue, the standard material from pathology archives.